Related Experiment Video
Updated: Jun 23, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
[Third generation beta-blockers: current state of research on vasodilating beta-blockers]
Dennis Ladage1, Christian Reidenbach, Albert Lichtenthal
1Abteilung für Molekulare und Zelluläre Sportmedizin, Institut für Herz/Kreislaufforschung, Deutsche Sporthochschule Köln, Germany.
Wiener Medizinische Wochenschrift (1946)
|May 5, 2009
Summary
Nebivolol is a unique beta-blocker that widens blood vessels by releasing nitric oxide. Its pleiotropic effects benefit cholesterol, triglycerides, and reduce blood clotting, making it distinct from other beta-blockers.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Nebivolol is a third-generation beta-blocker with vasodilating properties.
- It exhibits high selectivity for the beta(1)-adrenoceptor.
Purpose of the Study:
- To highlight the unique pharmacological profile of nebivolol.
- To emphasize its pleiotropic effects and clinical recommendations.
Main Methods:
- Review of nebivolol's mechanism of action.
- Analysis of its effects on nitric oxide release, lipid profile, and thrombocyte activity.
Main Results:
- Nebivolol acts as an agonist at beta(3) adrenoceptors and estrogen receptors, releasing nitric oxide via eNOS.
- It positively influences cholesterol and triglycerides and decreases thrombocyte activity.
- Nebivolol is recommended by the European cardiac society for metabolic syndrome patients.
Conclusions:
- Nebivolol's distinct properties, including nitric oxide release and pleiotropic effects, differentiate it from other beta-blockers.
- Its beneficial effects on cardiovascular risk factors support its use in specific patient populations.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...